References
- Gislason GH, Rasmussen JN, Abildstr⊘m SZ, Gadsb⊘ll N, Buch P, Friberg J, Rasmussen S, K⊘ber L, Stender S, Madsen M, Torp-Pedersen C. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006;27 (10):1153–1158.
- Yetgin T, van der Linden MM, de Vries AG, Smits P, van Mechelen R, Yap S, Boersma E, Zijlstra F, van Geuns R; CCR Study Investigators. Current discharge management of acute coronary syndromes: data from the Rijnmond Collective Cardiology Research (CCR) study. Neth Heart J 2014;22 (1):20–27.
- Danchin N, Cambou JP, Hanania G, Kadri Z, Genès N, Lablanche J, Blanchard D, Vaur L, Clerson P, Guéret P; USIC 2000 Investigators. Impact of combined secondary prevention therapy after myocardial infarction: data from a nationwide French registry. Am Heart J 2005;150 (6):1147–1153.
- Goldberger JJ, Bonow RO, Cuffe M, Dyer A, Rosenberg Y, O'Rourke R, Shah P, Smith S Jr; PACE-MI Investigators. Beta-blocker use following myocardial infarction: low prevalence of evidence-based dosing. Am Heart J 2010;160 (3):435–442.
- Shah BR, Drozda J, Peterson ED. Leveraging observational registries to inform comparative effectiveness research. Am Heart J 2010;160 (1):8–15.
- Lee HY, Cooke CE, Robertson TA. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. J Manag Care Pharm 2008;14 (3):271–280.
- Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353 (5):487–497.
- Keller P-F, Carballo S, Carballo D. Present and future of secondary prevention after an acute coronary syndrome. EPMA J 2011;2 (4):371–379.
- Quiles J, Miralles-Vicedo B. Update: Acute coronary syndromes (IX). Secondary prevention strategies for acute coronary syndrome. Rev Esp Cardiol 2014;67 (10):844–848.
- Bays H. Statin safety: an overview and assessment of the data–2005. Am J Cardiol 2006;97 (8A):6C–26C.
- Newman C, Tsai J, Szarek M, Luo D, Gibson E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 2006;97 (1):61–67.
- Amsterdam EA, Wenger NK, Brindis RG, Casey D Jr, Ganiats T, Holmes D Jr, Jaffe A, Jneid H, Kelly R, Kontos M, Levine G, Liebson P, Mukherjee D, Peterson E, Sabatine M, Smalling R, Zieman S. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes. J Am Coll Cardiol 2014;64 (24):2713–2714.